Evidence map›Paper›PMID 36894957›Full record

ArticleBMC chemistry2023

A novel heterogeneous acid-base nano-catalyst designed based on graphene oxide for synthesis of spiro-indoline-pyranochromene derivatives.

Soghra Khabnadideh, Khashayar Khorshidi, Leila Amiri-Zirtol

Open access · goldAbstract read
In one paragraph

Article in BMC chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Soghra KhabnadidehPharmaceutical Science Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Khashayar KhorshidiPharmaceutical Science Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Leila Amiri-ZirtolPharmaceutical Science Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. l.amiri@rocketmail.com.
Shiraz University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nano graphene oxide/3-aminopyridine has been introduced as a new, efficient and robust heterogeneous organic catalyst for synthesis of spiro-indoline-pyranochromene derivatives. Nano graphene oxide/3-aminopyridine was provided in an easy and green way from GO. Firstly, graphene oxide (GO) was synthesized and then 3-aminopyridine was immobilized with covalent bonds on its surface as a nitrogenous organic compound, in this step we didn't use any organic or toxic substance. This bonding was easily performed due to the presence and reactivity of the epoxy groups in the GO structure. Because of its vast-surface nano-layers, GO could be effective in appropriate dispersion of 3-aminopyridine on its surface and increasing the catalyst performance. The new catalyst was analysed using different microscopic and spectroscopic techniques such as Fourier-transform infrared (FT-IR), field emission scanning electron microscope (SEM), energy-dispersive X-ray spectroscopy (EDS), X-ray diffraction (XRD) and thermogravimetric analysis (TGA). Our results showed that the distance between GO plates was increased in the presence of the modifying agent. This is due to the placement of the organic compound between the GO sheets. Finally, the ability of our new nano-catalyst in the synthesis of some spiro-indoline-pyranochromene and dihydropyranochromene derivatives was evaluated and acceptable results were obtained. Eight analogous of spiro-indoline-pyranochromene (4a-4 h) were synthesized in high yields and characterized. Using 3-aminopyridine as an organic and efficient catalyst, its stabilization by a simple method on GO, recycling of the catalyst up to 7 times and obtaining a highly pure product were the points that made the present work more attractive.

Indexed as

3-AminopyridineGraphene oxideOrganocatalyst

Identifiers

PMID36894957
PMCPMC9999615
OpenAlexW4323654817

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.